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Scope: Partially hydrolyzed cow’s milk proteins are used to prevent cow’s milk allergy in chil-
dren. Here we studied the immunomodulatory mechanisms of partial cow’s milk hydrolysates
in vivo.
Methods and results: Mice were sensitized with whey or partially hydrolyzed whey using
cholera toxin. Whey-specific IgE levels were measured to determine sensitization and immune
cell populations from spleen, mesenteric lymph nodes and Peyer’s patches after oral whey
administration were measured by flowcytometry. Whey-specific IgE and IgG1 levels in partial
whey hydrolysate sensitized animals were enhanced, but challenge did not induce clinical
symptoms. This immunomodulatory effect of partial whey hydrolysate was associated with
increased regulatory B and T cells in the spleen, together with a prevention of IgM-IgA class
switching in the mesenteric lymph nodes and an increased Th1 and activated Th17 in the
Peyer’s patches.
Conclusion: Partial hydrolysate sensitization did not induce whey-induced clinical symptoms,
even though sensitizationwas established. Increased regulatory cell populations in the systemic
immune system and a prevention of increased total Th1 and activated Th17 in the intestinal
immune organs could contribute to the suppression of allergic symptoms. This knowledge is
important for a better understanding of the beneficial effects of hydrolysates.
Keywords:
Breg / Cow’s milk allergy / Infant formula / Partial whey hydrolysate / Sensitization
study
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
In a conventional homeostatic situation, the intestinal
immune system maintains oral tolerance. In this state, no
Correspondence:M. B. Gea Kiewiet
E-mail:m.b.g.kiewiet@umcg.nl
Abbreviations: Breg, regulatory B cells;CT, cholera toxin; FCS, Fe-
tal calf serum;MLN,mesenteric lymphnodes; PP, Peyer’s patches;
RT, room temperature; Treg, regulatory T cells
immune response against harmless food derived molecules
is induced, while the immune system is still able to evoke
a protective immune response against harmful pathogens
[1]. When this homeostasis is disturbed, food allergy can
develop. Cow’s milk allergy is one of the major food allergies
in children, with a prevalence of 2–3% [2]. Although the
awareness of cow’s milk allergy as a serious health issue is
growing [3], the only therapy available is allergen avoidance
[4].
Avoidance of allergens can be accomplished by allergen
destruction. Enzymatic hydrolysis destroys linear and
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structural epitopes and is considered the most effective
mode to reduce allergenicity. Depending on the hydrolysis
degree, hydrolyzed proteins are either used to treat existing
cow’s milk allergy (extensively hydrolyzed) or to prevent
allergic symptom development (partially hydrolyzed). The
efficacy of partially hydrolyzed cow’s milk protein based
hypoallergenic infant formulas in reducing the development
of cow’s milk allergy in at-risk infants was demonstrated in
multiple clinical trials [5, 6]. Recently it had been recognized
that postponing the contact with intact protein by destruction
of epitopes might not be the only explanation for the
hypoallergenic properties of partially hydrolyzed cow’s
milk proteins. It was demonstrated that especially partial
hydrolysates can actively modulate immune responses [7].
During hydrolysis, smaller peptides are released from the
intact protein. These peptides were found to possess a range
of immunomodulatory capacities [8–11]. This suggests that
specific peptides might contribute to hypoallergenic effects
of hydrolysates. This has been confirmed in mouse mod-
els in which pre-treatment with partially hydrolyzed cow’s
milk proteins before sensitization induced oral tolerance and
reduced allergic responses to whey protein [12, 13]. This ef-
fect is associated with an increased percentage of regulatory
T cells (Treg) in the mesenteric lymph nodes [13]. Transfer-
ring immune cells including Treg from tolerized mice pro-
tected recipients fromdeveloping an acute skin response after
a challenge with whey [12,14]. No oral tolerance was induced
when pre-treatment was performed with proteins that were
more extensively hydrolyzed [12, 13].
Previously, we used an in vitro technology platform
to screen immunomodulatory effects of a range of cow’s
milk proteins in a systematic way [15]. Our data showed
that partially hydrolyzed whey induced a higher anti-
inflammatory/pro-inflammatory cytokine ratio than intact
whey or extensively hydrolyzed whey. Since higher levels of
anti-inflammatory cytokines have a regulatory function in al-
lergy [16,17], we hypothesized that partially hydrolyzed whey
may also have in vivo immunomodulatory effects in a cow’s
milk allergy setting. Therefore, we investigated the effect of
the most potent partial hydrolysate with immunomodulatory
capacities in a cow’s milk allergy mouse model. This mouse
model has been developed and validated to be used in the
pre-clinical safety evaluation of hypoallergenic formulas [18].
The IgE-mediated allergic response in these animals, together
with the orally induced sensitization, can be closely followed.
In this study, mice were sensitized with either whey or its
partial hydrolysate by using cholera toxin. To study whether
sensitization with the partially hydrolyzed proteins can in-
duce clinical allergic symptoms, we investigated acute skin
response, body temperature, and anaphylactic reactions fol-
lowing intradermal whey administration. Whey-specific IgE
and IgG1weremeasured in serum.To assess the role of possi-
ble immunomodulatory effects of the hydrolysate, we studied
immune cells populations in the spleen, Peyer’s patches (PP)
and mesenteric lymph nodes (MLN) following an oral whey
challenge.
2 Materials and methods
2.1 Cow’s milk proteins and hydrolysates
Intact whey (WPC80) and whey protein hydrolysate were
provided by FrieslandCampina (Amersfoort, the Nether-
lands). The whey protein was partially hydrolyzed by two-step
digestion to produce the hydrolysate with a hydrolysis degree
of 9.2%. Peptide and amino acid patterns were obtained
with RP-UHPLC method. Separations were performed on
a Hypersil GOLD analytical column with Spherical silica
packing (1.9 m, 175A˚, 2.1 × 100 mm). The gradient elution
was carried out with a mixture of 0.1% trifluoroacetic acid
(TFA) and 1% acetonitrile (ACN) in water and 01% TFA and
90% ACN in water.
2.2 Mice
Three- to four-week old pathogen-free female C3H/HeOuJ
mice were purchased from Charles River Laboratories (Saint
Germain sur l’Arbresle, France). Mice were housed in the
animal facility of the University Utrecht and maintained on
semi-purified cow’s milk protein-free mouse chow (Research
Diet Services, Wijk bij Duurstede, The Netherlands). Animal
care and use were performed in accordance with the guide-
lines of the Dutch Committee of Animal Experiments.
2.3 Experimental set-up
Two groups of mice (both n = 8) were sensitized by oral
administration on day 0, 7, 14, 21, and 28 of 20 mg whey or
whey hydrolysate, in 0.5 mL PBS containing 10 g cholera
toxin (CT) (Quadratech Diagnostics, Epsom, UK) to break
tolerance (Fig. 1). Non-sensitized mice (n = 8) received only
cholera toxin inPBS (CTgroup). To determine clinical allergic
symptoms, animals were challengedwith intact whey. On day
33, mice were intradermally challenged in the ear with 10 g
whey after which acute allergic skin responses, anaphylactic
reactions and body temperature were determined. After 6 h,
mice were orally challengedwith 50mgwhey. Eighteen hours
later, animals were terminated and blood, spleen, MLN and
PP of six out of eight mice were collected for each group. The
organs were kept in RPMI containing decomplemented fetal
calf serum (FCS) on ice until processing for flow cytometry.
Blood samples were centrifuged for 15 min at 13.500 rpm
and stored at –20C.
2.4 Acute allergic skin response
In all animals, the acute allergic skin response was deter-
mined 1 h after the intradermal challenge with 10 g whey in
the ear pinnae. Ear thicknesswasmeasured induplicate using
a digital micrometer (Mitutoyo, Veenendaal, The Nether-
lands). The allergen-specific net ear swelling was calculated
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Figure 1. Experimental setup. In order to induce sensitization the
mice received 20 mg intact whey or whey hydrolysate homog-
enized in PBS and mixed with 10 g cholera toxin on day 0, 7,
14, 21 and 28 via the oral route. The control group only received
cholera toxin on those days. On day 33, mice were first intrader-
mally challenged in the ear with 10 g intact whey after which
the acute skin response, anaphylactic reaction and body temper-
ature were measured. After 6 h, mice were orally challenged with
50 mg intact whey. On day 34 (18 h after the oral challenge) the
animals were terminated and serum and organs were collected.
by correcting the allergen-induced ear thickness with the
basal ear thickness. The delta ear swelling is expressed asm.
2.5 Anaphylactic shock score and body temperature
To evaluate the sensitization capacity of the samples, the ana-
phylactic reaction and body temperature were determined
after the intradermal whey challenge. To establish the shock
severity, a validated anaphylactic scoring table (0: no symp-
toms; 1: scratching nose and mouth; 2: swelling around the
eyes and mouth, pillar erecti, reduced activity, higher breath-
ing rate; 3: shortness of breath, blue rash around the mouth
and tail, higher breathing rate; 4: no activity after stimula-
tion, shivering and muscle contractions; 5: death by shock)
was used, as adapted from Li et al. [19]. To measure changes
in body temperature, all mice were given an implantable elec-
tronic ID transponder (Bio Medic Data Systems, Delaware,
USA) on day 16.
2.5 Measurement of whey-specific serum IgE and
IgG1
Concentrations of serum whey-specific IgE and IgG1 were
determined by ELISA as described previously [12]. In short,
Microlon plates (Greiner Bio-one, Monroe, USA) were
coated with whey protein for 18 h at 4C. Plates were washed
after each incubation step. Serum samples were applied and
incubated for 2 h at room temperature (RT), followed by
incubation with biotin-labeled IgE or IgG1 for 90 min. The
plates were incubated with streptavidin-horseradish peroxi-
dase for 1 h at RT and developed with o-phenylendiamine
(Sigma-Aldrich). The reaction was stopped with 4 M H2SO4
and absorbance was measured at 490 nm on a Benchmark
microplate reader (Bio-Rad, Hercules, CA, USA). In the
IgG1 ELISA, serum samples were diluted 50 times.
2.6 Flow cytometer analysis of T and B cell subsets
in spleen, MLN, and PP
T and B cell (sub)populations were investigated after the
oral challenge using flow cytometry. Cells were isolated
from the spleen, MLN and PP. The spleen is considered to
be representative for the systemic immune response [20].
The MLN are the draining lymph nodes from the gut [21],
and the PP represents the local intestinal immune response
[22].
All procedures were performed on ice. In order to iso-
late cells, organs were crushed between microscope slides in
2mL ofmedium (RPMIwith 10% decomplemented FCS). To
lyse erythrocytes, the spleen cell suspensions were incubated
for 10 min with 4 mL ammonium chloride solution. Spleen
cell suspensions were centrifuged at 1800 rpm for 5 min at
4C and washed with 4 mL FACS buffer 2% (PBS supple-
mented with 2% decomplemented FCS). Cell suspensions
from all organs were filtered using a cell suspension filter
(Greiner, Alphen aan de Rijn, The Netherlands), and counted
using a coulter counter (Beckton Dickinson BV, Breda, the
Netherlands).
To stain the T and B cell subsets, cells (1 × 106/well) were
transferred to a roundbottom 96-wells plate and centrifuged
at 1800 rpm for 5min at 4C. Cells were resuspended in 25L
extracellular blocking buffer (20% normal rat serum, 2% FC
(CD16/CD32) block, in FACS buffer 10%) for 15 min. After
centrifuging, cells were resuspended in 25 L extracellular
antibody mix (antibodies as listed in supplementary file 1 or
isotype controls, in FACS buffer 10% containing 5% normal
rat serum) and incubated for 30 min in the dark. After
washing and fixation for 30 min in fix-lysing buffer (Beckton
Dickinson BV, Breda, the Netherlands) and washing again,
cells were incubated with 200 L permeabilization buffer
(eBioscience, Vienna, Austria) for 10 min. Cells were
resuspended in 50 L intracellular blocking buffer (20%
normal rat serum in permeabilization buffer) and incubated
for 15 min. After centrifuging, cells were resuspended in 50
L intracellular antibody mix (antibodies as listed in supple-
mentary file 1 or isotype controls, and 5% normal rat serum
in permeabilization buffer) for 30 min in the dark. Cells
were washed in permeabilization buffer three times, and
resuspended in 100 L FACS buffer. Cells were analyzed on
a FacsVerse flow cytometer. UltraComp eBeads were used to
set compensation values for the antibody panels. The corre-
sponding isotype control antibodies were used to set positive
gates, using a margin of 1%. FlowJo VX software (FlowJo,
Oregon, USA) was used to analyze lymphocyte subsets.
Flow cytometry gating strategies are described in the sup-
plementary files 2, 3 and 4. Single cells were selected by gating
FSC-W vs FSC-H. CD3 was used as a marker for T cells, and
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Figure 2. Characterization of partial whey hydrolysate. Peptide
and amino acid patterns were obtained with a RP-UHPLCmethod
(A). This was used to calculate the molecular weight distribution
(B).
within this T cell population we distinguished Thelper cells
(CD4+) and cytotoxic T cells (CD8+). Within the Thelper cell
populationwe identified Th1 cells (Tbet+), Th2 cells (Gata3+),
Treg (FoxP3+) and Th17 cells (RoRT+). B220 was used as
a B cell marker. Within this B cell population, regulatory B
cells (Breg) were distinguished (CD5+). Also within B220+
cells, IgM+ and IgA+ cells were measured to indicate class-
switching. CD138+ cells were considered to be plasma cells.
Within all populations, CD69+ cells were considered to be
activated cells [23].
2.7 Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 software (La Jolla, CA, USA). For all data, normality was
tested using a Kolmogorov–Smirnov test. The earswelling,
body temperature and anaphylactic shock score data were
normally distributed and shown as mean ± standard devia-
tion (SD). Significant differences were assessed by one-way
analysis of variance (ANOVA) followed by Tukey’s multiple
comparison test. The antibodies and flow cytometry data were
not normally distributed, and therefore the data were shown
as median ± range. Significant differences were tested using
a Kruskall–Wallis test followed by Dunn’s multiple compar-
isons test. A p-value of <0.05 was considered to indicate a
significant difference.
3 Results
3.1 Chemical characterization of partial whey
hydrolysate
The whey protein hydrolysate was obtained by a two-step hy-
drolysis of whey protein (WPC80). The degree of hydrolysis of
the obtained hydrolysate was 9.2%. Peptide pattern (reversed
phased chromatography) and molecular weight distribution
are shown in Fig. 2. As shown in Fig. 2B, the hydrolysate con-
tained mainly peptides smaller than 5 kD, and is therefore
considered partially hydrolyzed.
Figure 3. Whey-specific IgE and IgG1 response and clinical symptoms in mice after the challenge with whey. IgE and IgG1 levels were
significantly increased in intact whey and whey hydrolysate sensitized animals compared to the CT group (A and B). Clincial symptoms
being acute skin response, symptoms of anaphylactic shock and a drop in body temperature were all increased in the whey sensitized
animals, but not in the hydrolysate sensitized mice (C– E). Significant differences were indicated by *.
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3.2 Whey hydrolysate sensitized mice showed an
IgE and IgG1 response but no clinical signs of
anaphylactic shock and acute skin response
after whey administration
Whey sensitized mice showed increased levels of IgE com-
pared to the non-sensitized control group that only received
cholera toxin (p<0.01) (Fig. 3A). Partial hydrolysis of whey
could not prevent whey-specific IgE enhancement as IgE
levels were also significantly elevated in whey hydrolysate
sensitized mice compared to the CT group (p<0.05). Whey-
specific IgG1 levels were also elevated in both the whey and
hydrolysate group compared to the control group (p<0.01
and p<0.05) (Fig. 3B). To study the allergic response against
whey, the acute skin response was measured in mice after
an intradermal whey challenge. As expected, an increased
acute skin response was detected in intact whey protein sen-
sitized animals (p<0.0001) compared to the CT group (Fig.
3C). Interestingly, sensitization with a hydrolyzed whey did
not lead to an acute skin response upon a whey challenge
(Fig. 3C). Two other clinical parameters were measured after
the acute skin response, i.e. the presence of an anaphylac-
tic shock and body temperature. Mice sensitized with intact
whey protein showed low to severe anaphylactic symptoms
(p<0.0001), while whey hydrolysate sensitized animals did
not show anaphylactic symptoms (Fig. 3D). A drop in body
temperaturewas clearly present in thewhey sensitized animal
group (p<0.01) but absent in the whey hydrolysate sensitized
animals (Fig. 3E).
3.3 Sensitization with whey hydrolysate induced
systemic changes in T cell percentage, subtypes,
and activation after oral whey administration
Since we observed that food allergy related clinical symptoms
were absent in hydrolysate sensitized mice despite the
presence of whey-specific IgE, we questioned whether
whey hydrolysate could have an immunomodulating effect.
Therefore, we studied the differences in immune responses
between intact whey and hydrolysate treated animals and CT
controls. We first investigated the systemic immune system
after the oral challenge. As shown in Fig. 4, the total percent-
age of lymphocytes did not differ between groups, but the
Figure 4. Percentages of lymphocytes, T cells and T(helper) cell subsets in the spleen. A decrease in total percentage of T cells and
cytotoxic T cells was observed in the hydrolysate group compared to the CT group, while the percentage of Thelper cells and activated
T cells increased. Activated Th2 and Tregs were increased in hydrolysate sensitized animals, but not in whey sensitized mice. Statistical
differences were indicated by *.
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percentage of T cells in the spleens of mice sensitized with
whey hydrolysate was significantly decreased compared to the
CT group (p<0.001), while there were no differences between
the whey group and the CT group. The hydrolysate sensitized
animals showed significant differences compared to the
whey group and the CT group for several T cell subsets. They
had a higher percentage of Thelper cells (p<0.05) compared
to the whey group and a decreased percentage of cytotoxic
T cells compared to the CT group (p<0.01) and whey group
(p<0.05). The whey group showed no differences in these
T cell subtypes compared to the CT group. Also, hydrolysate
sensitized animals showed a higher percentage of activated
Thelper cells (p<0.05) compared to the CT group. Activated
cytotoxic T cell percentages did not differ between any group.
3.4 Percentage of activated Th2 and Treg increased
in the spleen of whey hydrolysate sensitized
mice after an oral whey challenge
As food allergy is considered to be a Th2 type immune re-
sponse and balanced by Treg cells, we decided to further
explore the different subsets of splenic Thelper cells. While
the total percentages of Th1, Th2, Treg and Th17 cells did
not differ among groups (Supporting Information file 5), dif-
ferences were found when analyzing the activated T-cells, i.e.
CD69 positive cells, within the subsets (Fig. 4). No effects
on the percentage of activated Th1 cells were observed, while
the percentage of activated Th2 cells was increased in the
hydrolysate group compared to the CT group (p<0.05), but
not in the whey group. However, the higher percentage of
activated Th2 cells was accompanied by a significantly in-
creased percentage of activated Treg cells in the hydrolysate
group compared to the CT group (p<0.01). No effects where
observed in the whey group compared to the CT group. The
percentages of activated Th17 cells in the spleen did not differ
between any group.
3.5 Percentage of CD5+ Breg was increased in the
spleen of whey hydrolysate sensitized mice after
an oral challenge
Thelper cells in the spleen are found to be important in the
activation and class-switching of B cells, which play a crucial
role in the development of food allergy [24]. Therefore, it was
investigated whether sensitization with a whey hydrolysate
affected B cell subsets after an oral whey challenge. As shown
in Fig. 5, the total percentage of B cells was decreased in the
hydrolysate group compared to the CT group (p<0.05), but
the percentage of B cells of the whey group did not differ
from the CT group. The percentage of activated B cells did
not differ among groups. Furthermore, a significant increase
in the percentage of Breg was observed in the spleens of whey
hydrolysate sensitized mice compared to the whey group
(p<0.05). The whey group did not differ significantly from
the CT group. No differences in percentage of plasma cells,
Figure 5. Percentages of B cells and B cell subsets in the spleen.
The total percentage of B cells was decreased in hydrolysate sen-
sitized mice compared to the CT group. The percentages of Breg
were increased in mice sensitized with hydrolysate. Statistical
differences were indicated by *.
IgM+IgA- and IgM-IgA+ B cells were observed between
groups.
3.6 In the MLN, sensitization with a whey
hydrolysate decreased activated Th1 cells and
prevents the class-switching to IgA
Since we observed multiple hydrolysate-specific effects in the
systemic immune system, we investigated possible differ-
ences in the local intestinal immune organs, since the mu-
cosal immune system is the primary site where the induction
of an allergic reaction against orally administrated antigens
occurs [25]. Effects in the intestine might affect the systemic
immune response [26]. We first studied differences in the
MLN, since the MLN are assumed to play a pivotal role in
food allergy and maintaining oral tolerance [27]. We found a
decrease of the total percentage of lymphocytes in the whey
hydrolysate sensitized animals compared to the CT group
(p<0.05), but therewas no difference between thewhey group
and CT group (Fig. 6). The total percentage of T cells was in-
creased in the whey group compared to the hydrolysate group
(p<0.05). Activated cytotoxic T cells were slightly increased
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Figure 6. Percentages of lymphocytes, T cells and T(helper) cell subsets in the MLN. The total percentage of lymphocytes was decreased
in hydrolysate sensitized mice, but not in whey sensitized mice. The percentages of T cell increased in the whey group compared to the
hydrolysate group. The percentage of activated Th1 cells was decreased in animals sensitized with whey hydrolysate compared to the CT
group. Activated cytotoxic T cells slightly increased in the hydrolysate group compared to the whey group. Statistical differences were
indicated by *.
in the whey hydrolysate group compared to the whey group
(p<0.05). Also, when analyzing the activated Thelper subsets,
sensitization with whey hydrolysate was found to result in a
decreased percentage of activated Th1 cells compared to the
CT group (p<0.01) (Fig. 6). This effect was not seen in the
whey group. We found no differences when analyzing total
percentage of Thelper cells and cytotoxic T cells, activated
Thelper cells (Fig. 6), total Th1, Th2, Treg and Th17 cells
(Supporting Information file 6), and activated Th2, Treg and
Th17 cells (Fig. 6).
For the B cells, we found no differences among groups
for the total percentage of B cells, activated B cells, Breg, and
plasma cells (Fig. 7). However, when focusing on antibody
producing cells, we found that class-switching in B cells was
different among groups. In the group of mice sensitized with
whey the percentage of IgM+IgA-B cells decreased compared
to the hydrolysate group (p<0.05), while the percentage of
IgM-IgA+ B cells increased compared the hydrolysate group
(p<0.05). This suggests that class-switching to IgA happened
after sensitization with intact whey. This did not occur in
mice sensitized with whey hydrolysate.
3.7 Increase of Th1, and activated Th17 and Treg
cells and decrease of Breg was prevented in the
PP of whey hydrolysate sensitized mice
The first immune organs to come into contact with antigen
after an oral challenge are the PP, located in the lamina pro-
pria of the intestine. They are important antigen sampling
sites [22], and were found to affect the systemic immune sys-
tem [26]. No differences were found for the total percentage
of lymphocytes, T cells, Thelper cells or cytotoxic T cells, acti-
vated Thelper cells and cytotoxic T cells, nor for activated Th1
and Th2 cells among groups in the PP (Fig. 8). However,mice
sensitized with intact whey showed increased activated Treg
(p<0.05) and Th17 (p<0.05) percentages compared to the CT
group (Fig. 8), while hydrolysate sensitizedmice did not show
these effects. Here, we did not only observe differences in ac-
tivated Thelper subsets, but also the total percentages of the
Th1 and Treg were increased after sensitization with whey
compared to the CT group (both p<0.05), while sensitization
with whey hydrolysate did not have such effects (Supporting
Information file 7).
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Figure 7. Percentages of B cells and B cell subsets in the MLN.
The percentage of IgM-IgA+ B cells was increased in whey sensi-
tized mice compared to the hydrolysate sensitized animals. Sta-
tistical differences were indicated by *.
Sensitization with whey or whey hydrolysate did not have
an effect on the total percentage of B cells, activated B cells,
plasma cells, and IgM and IgA expression of B cells (Fig.
9). When mice were sensitized with whey, a significant de-
crease in Breg was seen in the PP compared to the CT group
(p<0.05). This decrease was not observed in animals sensi-
tized with a whey hydrolysate.
4 Discussion
Recent findings suggest that besides the destruction of epi-
topes [28], immunomodulatory effects of hydrolysates can
be an underlying mechanism contributing to the hypoaller-
genic properties of partially hydrolyzed whey proteins [29].
However, most animal studies showing beneficial effects of
hydrolysates in allergy mainly focus on immunoglobulin lev-
els as a measure for sensitization [12,13,30–32], while only a
few studies investigated effects of whey hydrolysates on im-
mune populations involved in the allergic response [12, 14].
In this study, we investigated the effects of sensitization with
a partially whey hydrolysate on allergy parameters and serum
whey-specific IgE and IgG1 levels after an intradermal whey
challenge. To investigate immune effects, a range of immune
populations of both systemic and intestinal immune organs
was also measured after the oral whey challenge. We found
that anaphylactic shock was not induced in whey hydrolysate
sensitized mice, even though increased serum whey-specific
IgE and IgG1 levels were detected. In the spleen, sensitiza-
tion with the whey hydrolysate resulted in an increase of Breg
and activated Treg. In the local immune organs hydrolysis of
whey proteins prevented both IgM-IgA class switching (MLN)
and the increase of the percentage of Th1, activated Th17 and
activated Treg cells (PP) (Fig. 10).
We found that after sensitization with the whey hy-
drolysate, the intradermal challenge did not induce allergic
symptoms like an anaphylactic shock, drop in body temper-
ature and an acute skin response. This finding corresponds
with previous experiments in the same and other mouse
models using partially hydrolyzed whey proteins [12, 33, 34].
Interestingly, despite the absence of clinical symptoms, we
found a significantly increased whey-specific IgE response in
whey hydrolysate sensitized animals. This also corroborates
the findings of other groups showing no clinical symptoms
despite a high specific IgE response in sensitized mice
[35–37]. It should be noted that variability between individual
mice in the whey hydrolysate group was high. Four animals
in the group showed a high IgE response, while two
animals showed a low response and IgE levels were not
increased in two animals. However, high variability between
individual animals is a known phenomenon in sensitization
studies [38]. None of these animals developed clinical
symptoms.
As we observed IgE induction, our data suggest that the
partial whey hydrolysate still contains whey epitopes which
are recognized by the immune system. After hydrolysis 10%
of the total amount of proteins was still larger than 10.000
Da (Fig. 2B). It is likely that intact -lactalbumin (14 kD) and
-lactoglobulin (18 kD),which are themain allergens inwhey,
are still present in this 10.000 Da fraction [39]. Lower doses of
antigen were described before to be to induce a stronger Th2
response than higher doses [40, 41]. This could explain why
the IgE levels in the hydrolysate group are higher compared
to the IgE levels in the whey group.
Despite the increased whey-specific IgE levels, the
hydrolysate does not evoke an allergic reaction after an intra-
dermal challenge. We hypothesized that this could be due to
an immunomodulatory effect of the hydrolysate. To study the
immunomodulatory effects of whey hydrolysates, we studied
the immune populations in the spleen, MLN and PP after
an oral whey challenge. In this challenge model, antigens
will first encounter the PP and MLN, which may affect the
peripheral immune response. We found hydrolysate-induced
effects in the spleen, i.e. the peripheral immune response.
Some of these effects are associated with (food) allergy and
suggest that the whey hydrolysate does sensitize against
whey, which is in line with the detected increased IgE levels.
This includes an increased percentage of (activated) Thelper
cells and a decreased percentage of cytotoxic T cells [42, 43],
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Figure 8. Percentages of lymphocytes, T cells and T(helper) cell subsets in the PP. No differences between groups in percentages of total
lymphocytes, T cells and T cells subsets were observed. Activated Th17 and Treg cells were increased in the whey group compared to the
CT group. Statistical differences were indicated by *.
together with an increase in activated Th2 cells [44]. The
fact that despite this established sensitization no clinical
symptoms were observed, suggests a stimulated immune
regulatory effect of the whey hydrolysate. Such an im-
munomodulatory effect could be induced by Treg and Breg,
since we observed an increased percentage of these cells in
the spleen. The increased percentage of Treg in the spleen
may suppress mast cells and basophils, thereby suppressing
the effector phase of the allergic reaction [37]. Breg have been
recognized as an important suppressor cell in multiple dis-
eases, including cow’s milk allergy [45]. It was shown that an
adoptive transfer of CD5+ Breg from the MLN could reduce
the allergic responses in sensitized recipients [46]. The in-
duction of Treg and Breg by partially hydrolyzed whey could
therefore be a mechanism involved in the dampening of the
clinical allergic symptoms in the whey hydrolysate sensitized
mice.
During oral sensitization and challenge, the intestinal im-
mune cells are the first to encounter the administered anti-
gen. Food allergy might already be initiated at this intestinal
mucosal level as both the removal of the Peyer’s patches or
the MLN results in a decrease in allergic responses [26]. The
role of the MLN in oral tolerance and regulating the aller-
gic reaction has been studied most. However, we only found
differences in the B cell subset in the MLN. Whey sensi-
tization increased the percentage of IgA+IgM- B cells and
decreased the percentage of IgA-IgM+ cells, which indicates
class switching from IgM to IgA. However, this effect was not
observed in the hydrolysate sensitized group. B cells from the
MLN are known to migrate to the intestine to regulate local
protection by producing immunoglobulins [47]. In allergy,
coating of antigens by IgA could be an important protection
mechanism [48].
Although the Peyer’s patches play a crucial role in the
development of an allergic reaction in food allergy [26], it is
unknown which cell populations are involved. In our study,
after the oral challenge,multiple effects were found in Peyer’s
patches of whey sensitized animals which were lacking in
hydrolysate sensitized animals. These differences might be
associated with immune dysregulation and development of
an allergic reaction. Whey sensitized animals showed an in-
creased percentage of total Th1, activated Th17 and activated
Treg cells; these increases were not observed in animals sen-
sitized with the whey hydrolysate. An increase of Th1 and
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 9. Percentages of B cells and B cell subsets in the PP. The
percentage of Breg was decreased in mice sensitized with whey
compared to the CT group, while no effect was observed in hy-
drolysate sensitize animals. Statistical differences were indicated
by *.
Th17 cells might indicate intestinal dysregulation and the
start of proinflammatory processes [49, 50], which is com-
pensated by the increased numbers of Tregs, as suggested
previously [51]. These findings seem to be in line with the
finding of a decreased percentage of Breg in the PP of whey
sensitized animals but not in the whey hydrolysate sensi-
tized mice. A lowering of these cells was reported before to
precede intestinal inflammation and dysregulation [52, 53].
These dysregulated inflammatory processes and differences
between intact whey and hydrolyzed whey treated animals
might be due to intestinal differences initiated during the
systemic allergy development. Since we focused in this study
on the effects 18 hours after the last challenge, we do not have
full insight in the changes over time.
In summary, we showed that administration of a partially
whey hydrolysate can induce sensitization against intact whey
as expressed by increasedwhey-specific IgE levels, but that the
occurrence of clinical symptoms induced by a challenge with
intact whey was not observed. We suggest that the increase
of Breg and Treg in the spleen and a prevention of increased
Th1, Th17 and IgM-IgA class switching in the mucosal im-
mune organs in partial hydrolysate sensitized animals can
contribute to a suppression of clinical symptoms. We believe
that these data are a first stepwise analysis of immune cell
populations in different immune organs of whey and par-
tially hydrolyzed whey sensitized animals. This knowledge is
important for a better understanding of the beneficial effects
of hydrolysates.
BCAMVE, MBGK, PDV and MMF conceived and designed
the experiments. BCAMVEperformed the animal experiment and
MBGK performed the flow cytometry experiment and analyzed
Figure 10. Overview of effects in im-
mune cell populations observed in
the study. Many differences have
been observed in T and B cell popula-
tions between hydrolysate sensitized
animals (H), intact whey sensitized
animals (Wh) and non-sensitized an-
imals (CT). In the spleen of whey hy-
drolysate sensitized mice an increase
of Breg and activated Treg was ob-
served. In the local immune organs
hydrolyzation of whey proteins lead
to prevention of IgM-IgA class switch-
ing (MLN) and increased percentages
of Th1, and activated Th17 and Treg
cells.
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